Navigation Links
Medical Colleges, Confident of Meeting Standards Before 90-days deadline

The state governed medical colleges have not much to improve their standards, as stipulated by the Medical Council of India (MCI) //, which has given them a three month deadline to comply with the norms or face a risk of de-affiliation.

MCI is the authorized body that has the power to accord affiliation to medical colleges across the country, has issued a 90-day deadline for the three colleges, which is due to end in May.

A month has passed since the meeting, but Mahatma Gandhi Memorial Medical College, Hospital (Jamshedpur), Patliputra Medical College and Hospital (Dhanbad) and Rajendra Institute of Medical Sciences (Ranchi) have not done much to comply with guidelines.

Gajendra Thakur, a member of the executive body of MCI and president of the Bihar chapter of the Indian Medical Association (IMA). Thakur said: “The de-affiliation was deferred for 90 days on condition that the institutions improve the facilities to ensure bed occupancy in their hospitals.”

The area that need to be spruced up range from an inoperative ICU, CT scan facility, or even for that matter availability of teaching staff , which continues to haunt the medical colleges in question. Despite funds being provided to the hospitals to facilitate the requirements, precious little has bee done.

Jagannath Prasad, former acting director of RIMS and head of department, anaesthesia, said, “Steps are being taken to ensure that the deficiencies pointed out are rectified at the earliest.”

The colleges are hopeful of complying with the stipulations before the deadline is over.


'"/>




Page: 1

Related medicine news :

1. Indian Nationals with Foreign Medical Degrees can now practice in India
2. Meditation Works Medically
3. Sleep Disorders Could Indicate Other Medical Problems
4. Being Obese Increases Ones Risk Of A wrong Diagnosis During Medical Imaging
5. Hypnosis Found To Reduce Stress In Children During Medical Procedures
6. Stanford Medical Center Implements The First Virtual Cardiac Ultrasound
7. Ayurvedic Therapies Cashing In On Medical Tourism
8. Prevention And Timely Medical Care Can Help With Bug Bites
9. Government Organisation Proposes Strict Guidelines For SubStandard Medical Devices
10. Grant of $7 million for Orissa Medical College from Japan
11. Indian Hospitals – A Destination For Quality Medical Care

Post Your Comments:
(Date:11/25/2009)...BroadPoliticalEndorsements,Business,andPressJoinEf...re-USNewswire/--Onceagain,theNationalBipolarFounda...endorsingtheir"Safe,tilStable"program,whichisnowbe...bipolardisorder.Today,theNationalBipolarFoundation...sPriorityMailfromtheLt.GovernorofLouisianaMitchLan...
(Date:11/25/2009)...tuitous discovery that grew out of a collaboration...tially offer hope to the nearly 10 million America... , Also known as hardening of the arteries, per...ulatory problem in which narrowed arteries reduce ...ed a red flag for vascular disease, heart attack a...
(Date:11/25/2009)..., already used to fight rheumatoid arthritis, coul... , WEDNESDAY, Nov. 25 (HealthDay News) -- A...a and rheumatoid arthritis now also shows some pro... 1 diabetes. , The drug, rituximab (Rituxan), h...sulin, even though the disease had destroyed some ...
(Date:11/25/2009)... often plagued by neurological symptoms, study fin...ws) -- Neurological side effects are among the pot...sticular cancer who were treated with cisplatin-ba...study included 1,409 Norwegian men treated for uni...o took part in a follow-up survey conducted from 1...
(Date:11/25/2009)...RLINGTON,Va.,Nov.25/PRNewswire-USNewswire/--TheAme...ealthCareFraudActof2009,"S.2128,whichisdesignedtos...ventfraudinMedicare.ThebillwasintroducedbySen.Geor...eralprovisionstheAmericanAssociationforHomecareout...ociationproposedtoCongressinFebruary.Thoseprovisio...
Breaking Medicine News(10 mins):Health News:First Time-Door is Open for Family Discussion of Bipolar Disorder 2Health News:First Time-Door is Open for Family Discussion of Bipolar Disorder 3Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 2Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 3Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 4Health News:Type 1 Diabetes May Have a New Foe 2Health News:Type 1 Diabetes May Have a New Foe 3Health News:American Association for Homecare Endorses New U.S. Senate Bill, the 'Prevent Health Care Fraud Act of 2009' 2
...itute for Biological Studies during embryonic deve...produce// tentacle-like protrusions. These are cal...r destination. They guide the nerve cells through ...in the limb, scientists at the Salk Institute for ...
...s on obesity finalized to cause harm to children, .... Due to financial agreements made between t...ing this proposal, an unfit guideline was being ma...rican Medical Association has ‘tentatively decided...
...n makes women more disabled than men – study publi...s treatment procedures targeting to reduce stress ...reduce disability. This suggests that by targe... which involved 260 chronic pain patients from Roy...
...act fast when their reputation is at stake. Now th...nd credibility by doing something solid about all ...hicken, Wendy's, McDonald's and Burger King are al...nt. Jeff O'Neill, president and chief operat...
...omen, women overweight in their teens or later are...r. // This research was conducted by scientists at...The participants of the study were some 2,110 wome... were more likely to develop the disease compared ...
... portion of the horses in the Meath/Kildare region...g to reports from The Department of Agriculture an...ne Infectious Anemia, has an incubation period of ...s are being conducted to ascertain the facts. Ther...
Other Medicine News:Health News:Growth Factors Help Neurons to Reach Their Correct Destination 2Health News:Growth Factors Help Neurons to Reach Their Correct Destination 3Health News:New Obesity Guidelines Will Trouble US Children 2Health News:Depression And Chronic Pain Cause Disability In Women 2
(Date:11/25/2009)...rstCall/--Pharmasset,Inc.(Nasdaq: VRUS ),aclinical...evelopingandcommercializingnoveldrugstotreatvirali...endedSeptember30,2009.AtSeptember30,2009Pharmasset...investments. ,, PipelineUpdateand2009Highlight...ateNovember2009,anindependentDataMonitoringCommitt...
(Date:11/25/2009)...PRNewswire/-- FromNovember16-18,Phonak,theleadingm...hesecondeditionoftheHearingCareforAdultsConference...conferencebroughttogetherleadingexpertsinaginganda...whoworkeverydaywitholderpeoplewithhearinglossforan...searchandtrendsinhearingcareforolderpeople. ,,...
(Date:11/25/2009)...--TheFDAgrantedtraditionalapprovalforINTELENCE...riptaseinhibitor(NNRTI).INTELENCEistheonlyNNRTIspe...ltswhoareexperiencingvirologicfailurewithHIV-1stra...ents.Thetraditionalapprovalisbasedon48-weekdatafro...scurrentlymarketedintheU.S.byTibotecTherapeutics,a...
Breaking Medicine Technology:Pharmasset Reports Fiscal Year End 2009 Financial Results 2Pharmasset Reports Fiscal Year End 2009 Financial Results 3Pharmasset Reports Fiscal Year End 2009 Financial Results 4Pharmasset Reports Fiscal Year End 2009 Financial Results 5Pharmasset Reports Fiscal Year End 2009 Financial Results 6Pharmasset Reports Fiscal Year End 2009 Financial Results 7Pharmasset Reports Fiscal Year End 2009 Financial Results 8Phonak Successfully Hosts Hearing Care for Adults 2009 Conference 2Phonak Successfully Hosts Hearing Care for Adults 2009 Conference 3U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 2U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 3U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 4Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection 28CDI 29 5005 1Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection 28CDI 29 5005 2Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection 28CDI 29 5005 3Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection 28CDI 29 5005 4Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection 28CDI 29 5005 5Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection 28CDI 29 5005 6The Celebrate Wellness Expo Presents Motivational Speaker 26 Author Dr Robin L Smith and Spiritual Teacher 26 Author Rev Michael Bernard Beckwith 57249 1The Celebrate Wellness Expo Presents Motivational Speaker 26 Author Dr Robin L Smith and Spiritual Teacher 26 Author Rev Michael Bernard Beckwith 57249 2ATS Medical to Participate at the 2009 UBS Global Life Sciences Conference 57246 1ATS Medical to Participate at the 2009 UBS Global Life Sciences Conference 57246 2
... Therapeutics, Inc. (Nasdaq: TPTX ) today announ...ial evaluating three doses of NGX267 as a treatmen...jogren,s syndrome. NGX267 met the primary endpoin...ary flow production compared to placebo at all thr...e safe and well tolerated with few reports of exce...
... (Nasdaq: MITI ), a biopharmaceutical company de...atment of cancer, inflammation and autoimmune dise...agreement expanding its Committed Equity Financing... a private investment group. Under the terms of t... up to $75 million of capital during the next thre...
Other Medicine Technology:TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia 2TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia 3TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia 4TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia 5Micromet Expands Committed Equity Financing Facility to $75 Million 2Micromet Expands Committed Equity Financing Facility to $75 Million 3Micromet Expands Committed Equity Financing Facility to $75 Million 4Micromet Expands Committed Equity Financing Facility to $75 Million 5Micromet Expands Committed Equity Financing Facility to $75 Million 6
...ratories is a national reference laboratory and a ... and development. ARUP offers an extensive test me...linical and anatomic pathology. Owned by the Unive...more than half of the nation's university teaching...
...ratories is a national reference laboratory and a ... and development. ARUP offers an extensive test me...linical and anatomic pathology. Owned by the Unive...more than half of the nation's university teaching...
...ratories is a national reference laboratory and a ... and development. ARUP offers an extensive test me...linical and anatomic pathology. Owned by the Unive...more than half of the nation's university teaching...
...ratories is a national reference laboratory and a ... and development. ARUP offers an extensive test me...linical and anatomic pathology. Owned by the Unive...more than half of the nation's university teaching...
Medicine Products: